Indonesia vs Liberia: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Indonesia
0.7%
in 2024
Liberia
0.7%
in 2024
Indonesia rank
51st
Liberia rank
51st
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Indonesia
- Liberia
How they compare
Indonesia currently reports 0.7% against 0.7% in Liberia, a difference of 0.0%.
The two have swapped places 2 times across 10 shared years of data; in 2015 it was Liberia ahead.
Indonesia ranks 51st and Liberia ranks 51st of 246 countries.
Across the 2 decades both report, Indonesia averaged higher in 1 and Liberia in 1.
Head to head by decade
| Decade | Indonesia | Liberia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.9% | 1.2% | 0.3% | Liberia |
| 2020s | 0.8% | 0.7% | 0.1% | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Indonesia or Liberia?
- Indonesia, at 0.7% against 0.7% in Liberia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Indonesia and Liberia?
- 0.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Liberia?
- 10 years are reported by both, from 2015 to 2024.
- How do Indonesia and Liberia rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Indonesia ranks 51st and Liberia ranks 51st of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.